First launch for Daiichi Sankyo's long-acting inhaled flu drug
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has launched in Japan the long-acting inhaled neuraminidase inhibitor, Inavir (laninamivir octanoate hydrate), for the treatment of A and B type flu infections.